Autologous cultured chondrocytes - Biologic Drug Details

Summary for autologous cultured chondrocytes

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for autologous cultured chondrocytes

Recent Clinical Trials for autologous cultured chondrocytes

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Regen Lab SA	N/A

See all autologous cultured chondrocytes clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for autologous cultured chondrocytes Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for autologous cultured chondrocytes Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,011,811	2033-11-25	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	6,150,163	2019-01-13	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	8,029,992	2028-04-04	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	8,216,778	2028-11-06	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	8,709,711	2032-06-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for autologous cultured chondrocytes Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vericel Corporation	CARTICEL SM SERVICE	autologous cultured chondrocytes	Injection	103661	4,846,835	2007-06-15	Patent claims search
Vericel Corporation	CARTICEL SM SERVICE	autologous cultured chondrocytes	Injection	103661	6,355,006	2019-11-09	Patent claims search
Vericel Corporation	CARTICEL SM SERVICE	autologous cultured chondrocytes	Injection	103661	7,108,663	2021-12-20	Patent claims search
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,016,338	2036-12-20	Patent claims search
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,239,927	2037-07-26	Patent claims search

Market Dynamics and Financial Trajectory for Autologous Cultured Chondrocytes

Last updated: February 16, 2026

Overview

Autologous cultured chondrocytes (ACC) are cells derived from a patient's cartilage tissue, expanded in vitro, and re-implanted to regenerate damaged cartilage. The primary commercial application is in cartilage repair, notably osteoarthritis and focal cartilage defects. Despite its niche status, the therapy segment exhibits growth driven by technological advances, unmet clinical needs, and regulatory shifts.

Market Size and Growth Projections

• The global cartilage repair market was valued at approximately $1.5 billion in 2022, projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 8.1%.
• ACC therapies represent an estimated 20% of this figure, indicating a current valuation near $300 million.
• Growth drivers include rising osteoarthritis prevalence, aging populations, and increasing demand for minimally invasive regenerative procedures.

Key Market Players and Product Approvals

• DePuy Synthes (Johnson & Johnson): Cartilage repair products, including Autologous Chondrocyte Implantation (ACI), under the MACI brand.
• Vericel Corporation: Markets MACI in North America, with revenue of approximately $100 million in 2022, accounting for about 80% of its cell therapy revenue.
• Vericel's MACI: FDA-approved since 2016, targeting full-thickness cartilage defects in the knee for patients aged 15-55.

Regulatory and Reimbursement Environment

• FDA Approval: MACI was approved in 2016, providing a regulatory pathway clarity that reduces market uncertainty.
• CPT Coding: The American Medical Association established CPT codes for ACI procedures, facilitating reimbursement.
• Reimbursement Rates: In the U.S., reimbursed at approximately $15,000 to $20,000 per procedure, varying by payer and region, influencing adoption rates.

Market Challenges

• Manufacturing Complexity: The need for personalized cell culture, quality control, and logistical hurdles raises costs and limits scalability.
• Cost-Effectiveness: High procedure costs ($20,000–$30,000) and variable reimbursement restrict broader adoption, especially outside major markets.
• Competition from Alternatives: Allograft products, synthetic scaffolds, and emerging biotech therapies like stem cell treatments transgress ACC's market share.

Technological Trends and Innovation

• Use of scaffold-free approaches and minimally manipulative techniques reduce preparation times and costs.
• Gene editing and growth factor integration aim to improve efficacy and durability of cartilage repair.

Financial Trajectory Predictions

• Revenue growth hinges on technological refinement, expanded indications, and global acceptance.
• An annualized growth of approximately 8-10% is projected for the ACC segment, contingent on regulatory developments and reimbursement policies.
• Investment in manufacturing infrastructure and centralized cell banking could lower costs and accelerate market penetration.
• Potential for expansion into osteoarthritis treatment via early intervention could open multi-billion-dollar opportunities, though regulatory hurdles remain.

Breakdown of Key Financial Indicators

Indicator	2022 Estimate	2030 Projection
Market Size	$1.5 billion	$3.2 billion
ACC Market Share	20%	25-30%
Revenue (Vericel MACI)	$100 million	$200 million+
CAGR	8.1%	8-10%

Strategic Outlook

• Investment Focus: Companies investing in scalable cell manufacturing, regulatory strategies, and clinical evidence for long-term efficacy tend to outperform.
• Partnerships: Collaborations with biotech firms and academic institutions drive innovation and reduce R&D costs.
• Global Expansion: Market growth outside North America and Europe depends heavily on approval pathways and healthcare reimbursement systems.

Key Takeaways

• The autologous cultured chondrocyte market is growing at a combined CAGR of approximately 8-10%.
• The primary revenue contributor is MACI, with $100 million recorded in 2022 and sustained growth predicted.
• Manufacturing complexity and reimbursement issues limit wider adoption.
• Technological advances and regulatory clarity will be critical in shaping future market dynamics and investor opportunities.
• Long-term growth hinges on expansion into osteoarthritis treatment and lowering production costs.

FAQs

1. What are the main hurdles for new entrants in autologous cultured chondrocyte markets?
   Manufacturing complexity, cost, regulatory approval processes, and establishing reimbursement pathways.

2. How does the pricing of ACC therapies compare globally?
   In North America, procedures cost $20,000–$30,000; in Europe and Asia, costs vary widely due to healthcare system differences.

3. What advancements could improve cost-effectiveness?
   Automation in manufacturing, centralized cell banking, and off-the-shelf allograft options.

4. Are there significant regulatory differences impacting global market expansion?
   Yes; regulatory pathways are well-defined in the U.S. via FDA approval, whereas many countries lack specific pathways for cell therapies, delaying market entry.

5. What emerging competitors threaten ACC market share?
   Stem cell-based therapies, allografts, and synthetic scaffolds, which may deliver similar or improved outcomes at lower costs.

References

1. Verified Market Research. Cartilage Repair Market Size & Share. 2023.
2. Vericel Corporation. Annual Report 2022.
3. U.S. Food and Drug Administration. FDA Approvals and Guidance for Cell Therapies. 2016.
4. AMA CPT Professional. 2022-CPT Code for Cartilage Repair.
5. Business Insider Intelligence. Global Regenerative Medicine Market Forecast. 2022.